Business
MedX Announces Further Closing of Non-Brokered Private Placement
MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: M...
About this update from Medx Health Corp.
[{"type":"text","content":"MedX Announces Further Closing of Non-Brokered Private Placement\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n\n MedX Health Corp.\n \n (“\n \n MedX\n \n ” or the “\n \n Company\n \n ”) (TSX-V:\n \n MDX\n \n ) is pleased to announce that, further to its Press Release dated April 7, 2025, announcing an Initial Closing, it has completed a further Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Further Closing comprised the issuance of 7,300,000 Units (as described below) and raised cash proceeds of $511,000, bringing the total amount raised so far to $1,456,000. Securities issued are subject to a regulatory “hold” period of four months and one day from the date of issuance. Further Closing(s) of the Placement will be subject to receipt of further subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Under this Non-Brokered Private Placement, the Company intends issue of up to a maximum of 35,714,858 Units at $0.07 per Unit (“Unit”) to raise a Maximum amount of $2,500,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (“\n \n Warrant\n \n (\n \n s\n \n )”), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. It is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders may participate in this Placement at a subsequent Closing, though to not more than 25% of the total funds raised. Qualified agents will receive a cash commission equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent’s warrants (“\n \n Agent’s Warrant(s)\n \n ”) equal to 8% of subscriptions introduced by such agent(s). Each Agent’s Warrant, which will be non-transferable, will entitle the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (“\n \n Agent’s Share Purchase Wa...